Overview
DEBRA Research, the research arm of DEBRA Austria, funds and advances translational research and clinical development for Epidermolysis Bullosa (EB) therapies. They build critical infrastructure including patient registries, biobanks, disease models, and clinical trial networks to accelerate EB treatment innovation. As a non-profit, they collaborate globally with academia, biotech, pharma, and patient organizations to turn research into curable solutions for EB.
Frequently asked questions
- What is DEBRA Research's primary focus?
- DEBRA Research focuses on translational research and clinical development to advance therapies and cures for Epidermolysis Bullosa (EB), a rare genetic skin disorder, through funding, infrastructure building, and global collaborations.
- What infrastructure capabilities do they provide for EB research?
- They develop essential EB research infrastructure such as patient registries, biobanks, preclinical models, disease atlases, and clinical trial networks to enable collaboration and accelerate therapy development.
- What are their geographic operations and partnerships?
- DEBRA Research operates worldwide from Munich, Germany, partnering with global entities including LEO Pharma (Denmark), Dermaliq, and UMC Groningen (Netherlands) for EB clinical trials and drug development.